Chemotherapy and Supportive Care Agents as Essential Medicines for Children with Cancer

Yoram Unguru, Melanie Brooke Bernhardt, Stacey L. Berg, Liza Marie-Johnson, Kimberly Pyke-Grimm, Catherine Woodman, Conrad V. Fernandez

Research output: Contribution to journalArticle

Abstract

In resource-rich countries, 5-year survival rates for children with cancer approach 85%. This impressive statistic is largely the result of integrating research with clinical care. At the core of this endeavor are multiagent combination chemotherapy and supportive care agents (CASCA). Most CASCAs belong to the class of sterile injectable drugs, which make up the backbone of many proven and life-saving pediatric oncology regimens. There are few if any alternative agents available to treat most life-threatening childhood cancers. In the United States, shortages of CASCAs are now commonplace. The consequences of drug shortages are far reaching. Beyond the economic costs, these shortages directly affect patients' lives, and this is especially true for children with cancer. Drug shortages in general and shortages of CASCAs specifically result in increased medication errors, delayed administration of life-saving therapy, inferior outcomes, and patient deaths. One way to mitigate drug shortages is to adopt an essential medicines list and ensure that these medications remain in adequate supply at all times. We argue for creation of a CASCA-specific essential medicines list for childhood cancer and provide ethical and policy-based reasoning for this approach. We recognize that such a call has implications beyond pediatric cancer, in that children with other serious disease should have an equal claim to access to guaranteed evidence-based medicines. We provide these arguments as an example of what should be claimed for medical indications that are deemed essential to preserve life and function.

Original languageEnglish (US)
JournalJAMA pediatrics
DOIs
StatePublished - Jan 1 2019

Fingerprint

Drug Therapy
Neoplasms
Pharmaceutical Preparations
Pediatrics
Medication Errors
Evidence-Based Medicine
Combination Drug Therapy
Survival Rate
Economics
Costs and Cost Analysis
Injections
Research
Therapeutics

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health

Cite this

Unguru, Y., Bernhardt, M. B., Berg, S. L., Marie-Johnson, L., Pyke-Grimm, K., Woodman, C., & Fernandez, C. V. (2019). Chemotherapy and Supportive Care Agents as Essential Medicines for Children with Cancer. JAMA pediatrics. https://doi.org/10.1001/jamapediatrics.2019.0070

Chemotherapy and Supportive Care Agents as Essential Medicines for Children with Cancer. / Unguru, Yoram; Bernhardt, Melanie Brooke; Berg, Stacey L.; Marie-Johnson, Liza; Pyke-Grimm, Kimberly; Woodman, Catherine; Fernandez, Conrad V.

In: JAMA pediatrics, 01.01.2019.

Research output: Contribution to journalArticle

Unguru, Yoram ; Bernhardt, Melanie Brooke ; Berg, Stacey L. ; Marie-Johnson, Liza ; Pyke-Grimm, Kimberly ; Woodman, Catherine ; Fernandez, Conrad V. / Chemotherapy and Supportive Care Agents as Essential Medicines for Children with Cancer. In: JAMA pediatrics. 2019.
@article{9b9aac2b718b4b588994cbdec98eb595,
title = "Chemotherapy and Supportive Care Agents as Essential Medicines for Children with Cancer",
abstract = "In resource-rich countries, 5-year survival rates for children with cancer approach 85{\%}. This impressive statistic is largely the result of integrating research with clinical care. At the core of this endeavor are multiagent combination chemotherapy and supportive care agents (CASCA). Most CASCAs belong to the class of sterile injectable drugs, which make up the backbone of many proven and life-saving pediatric oncology regimens. There are few if any alternative agents available to treat most life-threatening childhood cancers. In the United States, shortages of CASCAs are now commonplace. The consequences of drug shortages are far reaching. Beyond the economic costs, these shortages directly affect patients' lives, and this is especially true for children with cancer. Drug shortages in general and shortages of CASCAs specifically result in increased medication errors, delayed administration of life-saving therapy, inferior outcomes, and patient deaths. One way to mitigate drug shortages is to adopt an essential medicines list and ensure that these medications remain in adequate supply at all times. We argue for creation of a CASCA-specific essential medicines list for childhood cancer and provide ethical and policy-based reasoning for this approach. We recognize that such a call has implications beyond pediatric cancer, in that children with other serious disease should have an equal claim to access to guaranteed evidence-based medicines. We provide these arguments as an example of what should be claimed for medical indications that are deemed essential to preserve life and function.",
author = "Yoram Unguru and Bernhardt, {Melanie Brooke} and Berg, {Stacey L.} and Liza Marie-Johnson and Kimberly Pyke-Grimm and Catherine Woodman and Fernandez, {Conrad V.}",
year = "2019",
month = "1",
day = "1",
doi = "10.1001/jamapediatrics.2019.0070",
language = "English (US)",
journal = "JAMA Pediatrics",
issn = "2168-6203",
publisher = "American Medical Association",

}

TY - JOUR

T1 - Chemotherapy and Supportive Care Agents as Essential Medicines for Children with Cancer

AU - Unguru, Yoram

AU - Bernhardt, Melanie Brooke

AU - Berg, Stacey L.

AU - Marie-Johnson, Liza

AU - Pyke-Grimm, Kimberly

AU - Woodman, Catherine

AU - Fernandez, Conrad V.

PY - 2019/1/1

Y1 - 2019/1/1

N2 - In resource-rich countries, 5-year survival rates for children with cancer approach 85%. This impressive statistic is largely the result of integrating research with clinical care. At the core of this endeavor are multiagent combination chemotherapy and supportive care agents (CASCA). Most CASCAs belong to the class of sterile injectable drugs, which make up the backbone of many proven and life-saving pediatric oncology regimens. There are few if any alternative agents available to treat most life-threatening childhood cancers. In the United States, shortages of CASCAs are now commonplace. The consequences of drug shortages are far reaching. Beyond the economic costs, these shortages directly affect patients' lives, and this is especially true for children with cancer. Drug shortages in general and shortages of CASCAs specifically result in increased medication errors, delayed administration of life-saving therapy, inferior outcomes, and patient deaths. One way to mitigate drug shortages is to adopt an essential medicines list and ensure that these medications remain in adequate supply at all times. We argue for creation of a CASCA-specific essential medicines list for childhood cancer and provide ethical and policy-based reasoning for this approach. We recognize that such a call has implications beyond pediatric cancer, in that children with other serious disease should have an equal claim to access to guaranteed evidence-based medicines. We provide these arguments as an example of what should be claimed for medical indications that are deemed essential to preserve life and function.

AB - In resource-rich countries, 5-year survival rates for children with cancer approach 85%. This impressive statistic is largely the result of integrating research with clinical care. At the core of this endeavor are multiagent combination chemotherapy and supportive care agents (CASCA). Most CASCAs belong to the class of sterile injectable drugs, which make up the backbone of many proven and life-saving pediatric oncology regimens. There are few if any alternative agents available to treat most life-threatening childhood cancers. In the United States, shortages of CASCAs are now commonplace. The consequences of drug shortages are far reaching. Beyond the economic costs, these shortages directly affect patients' lives, and this is especially true for children with cancer. Drug shortages in general and shortages of CASCAs specifically result in increased medication errors, delayed administration of life-saving therapy, inferior outcomes, and patient deaths. One way to mitigate drug shortages is to adopt an essential medicines list and ensure that these medications remain in adequate supply at all times. We argue for creation of a CASCA-specific essential medicines list for childhood cancer and provide ethical and policy-based reasoning for this approach. We recognize that such a call has implications beyond pediatric cancer, in that children with other serious disease should have an equal claim to access to guaranteed evidence-based medicines. We provide these arguments as an example of what should be claimed for medical indications that are deemed essential to preserve life and function.

UR - http://www.scopus.com/inward/record.url?scp=85062342031&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85062342031&partnerID=8YFLogxK

U2 - 10.1001/jamapediatrics.2019.0070

DO - 10.1001/jamapediatrics.2019.0070

M3 - Article

C2 - 30830204

AN - SCOPUS:85062342031

JO - JAMA Pediatrics

JF - JAMA Pediatrics

SN - 2168-6203

ER -